Poolbeg Pharma PLC (POLBF)
Poolbeg Pharma PLC operates in the Biotechnology industry of the Healthcare sector, headquartered in London, GL, GB. The stock last traded at $0.10, up 0.00% on the session, giving a market capitalisation of $73.1M. On trailing twelve-month figures it carries a trailing P/E of -7.88, a net margin of 0.0%. Its beta of 1.81 implies it has historically moved more than the broad market.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Poolbeg Pharma PLC is most often compared with the following Healthcare names: